References
Abakushina EV (2015). The Technique of Flow Cytometry in Evaluation of
Nk-Cells and Their Activity. Klin Lab Diagn 60: 37-44.
Arnon TI, Achdout H, Levi O, Markel G, Saleh N, Katz G, et al.(2005). Inhibition of the NKp30 activating receptor by pp65 of human
cytomegalovirus. Nat Immunol 6: 515-523.
Asmana Ningrum R (2014). Human interferon alpha-2b: a therapeutic
protein for cancer treatment. Scientifica (Cairo) 2014: 970315.
Baaklini S, Afridi S, Nguyen TN, Koukouikila-Koussounda F, Ndounga M,
Imbert J, et al. (2017). Beyond genome-wide scan: Association of
a cis-regulatory NCR3 variant with mild malaria in a population living
in the Republic of Congo. PLoS One 12: e0187818.
Badolato R, Prandini A, Caracciolo S, Colombo F, Tabellini G, Giacomelli
M, et al. (2012). Exome sequencing reveals a pallidin mutation in
a Hermansky-Pudlak-like primary immunodeficiency syndrome. Blood
119: 3185-3187.
Barrow AD, Martin CJ, & Colonna M (2019). The Natural Cytotoxicity
Receptors in Health and Disease. Front Immunol 10: 909.
Bartel Y, Bauer B, & Steinle A (2013). Modulation of NK cell function
by genetically coupled C-type lectin-like receptor/ligand pairs encoded
in the human natural killer gene complex. Front Immunol 4: 362.
Baxter D (2014). Active and passive immunization for cancer. Hum Vaccin
Immunother 10: 2123-2129.
Biassoni R (2008). Natural killer cell receptors. Adv Exp Med Biol
640: 35-52.
Biassoni R, Cantoni C, Pende D, Sivori S, Parolini S, Vitale M, et
al. (2001). Human natural killer cell receptors and co-receptors.
Immunol Rev 181: 203-214.
Bloushtain N, Qimron U, Bar-Ilan A, Hershkovitz O, Gazit R, Fima
E, et al. (2004). Membrane-associated heparan sulfate
proteoglycans are involved in the recognition of cellular targets by
NKp30 and NKp46. J Immunol 173: 2392-2401.
Boivin WA, Cooper DM, Hiebert PR, & Granville DJ (2009). Intracellular
versus extracellular granzyme B in immunity and disease: challenging the
dogma. Lab Invest 89: 1195-1220.
Bottcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M,
Sammicheli S, et al. (2018). NK Cells Stimulate Recruitment of
cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control.
Cell 172: 1022-1037 e1014.
Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B, et al.(2009). The B7 family member B7-H6 is a tumor cell ligand for the
activating natural killer cell receptor NKp30 in humans. J Exp Med
206: 1495-1503.
Brondz BD (1964). In vivo and in vitro studies on the cytotoxic effect
of cellular and humoral antibodies. II - relation of immune lymphocytes
to homologous normal and tumor tissues. Vopr Onkol 10: 64-71.
Brusilovsky M, Radinsky O, Yossef R, Campbell KS, & Porgador A (2014).
Carbohydrate-mediated modulation of NK cell receptor function:
structural and functional influences of heparan sulfate moieties
expressed on NK cell surface. Front Oncol 4: 185.
Caligiuri MA (2008). Human natural killer cells. Blood 112:461-469.
Cao G, Wang J, Zheng X, Wei H, Tian Z, & Sun R (2015). Tumor
Therapeutics Work as Stress Inducers to Enhance Tumor Sensitivity to
Natural Killer (NK) Cell Cytolysis by Up-regulating NKp30 Ligand B7-H6.
J Biol Chem 290: 29964-29973.
Castro JE, Sandoval-Sus JD, Bole J, Rassenti L, & Kipps TJ (2008).
Rituximab in combination with high-dose methylprednisolone for the
treatment of fludarabine refractory high-risk chronic lymphocytic
leukemia. Leukemia 22: 2048-2053.
Chan A, Hong DL, Atzberger A, Kollnberger S, Filer AD, Buckley CD,
et al. (2007). CD56bright human NK cells differentiate into CD56dim
cells: role of contact with peripheral fibroblasts. J Immunol
179: 89-94.
Charrier M, Mezquita L, Lueza B, Dupraz L, Planchard D, Remon J,
et al. (2019). Circulating innate immune markers and outcomes in
treatment-naive advanced non-small cell lung cancer patients. Eur J
Cancer 108: 88-96.
Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T,
et al. (2001). Human natural killer cells: a unique innate
immunoregulatory role for the CD56(bright) subset. Blood 97:3146-3151.
Correia DV, Fogli M, Hudspeth K, da Silva MG, Mavilio D, & Silva-Santos
B (2011). Differentiation of human peripheral blood Vdelta1+ T cells
expressing the natural cytotoxicity receptor NKp30 for recognition of
lymphoid leukemia cells. Blood 118: 992-1001.
de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, & de Vries JE
(1991). Interleukin 10(IL-10) inhibits cytokine synthesis by human
monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp
Med 174: 1209-1220.
de Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, te Velde A, Figdor
C, et al. (1991). Interleukin 10 (IL-10) and viral IL-10 strongly
reduce antigen-specific human T cell proliferation by diminishing the
antigen-presenting capacity of monocytes via downregulation of class II
major histocompatibility complex expression. J Exp Med 174:915-924.
Delahaye NF, Barbier M, Fumoux F, & Rihet P (2007). Association
analyses of NCR3 polymorphisms with P. falciparum mild malaria. Microbes
Infect 9: 160-166.
Delahaye NF, Rusakiewicz S, Martins I, Menard C, Roux S, Lyonnet
L, et al. (2011). Alternatively spliced NKp30 isoforms affect the
prognosis of gastrointestinal stromal tumors. Nat Med 17:700-707.
Deng W, Gowen BG, Zhang L, Wang L, Lau S, Iannello A, et al.(2015). Antitumor immunity. A shed NKG2D ligand that promotes natural
killer cell activation and tumor rejection. Science 348:136-139.
DeVita VT, Jr., & Rosenberg SA (2012). Two hundred years of cancer
research. N Engl J Med 366: 2207-2214.
Dianat-Moghadam H, Rokni M, Marofi F, Panahi Y, & Yousefi M (2018).
Natural killer cell-based immunotherapy: From transplantation toward
targeting cancer stem cells. J Cell Physiol 234: 259-273.
Emmerich J, Mumm JB, Chan IH, LaFace D, Truong H, McClanahan T, et
al. (2012). IL-10 directly activates and expands tumor-resident CD8(+)
T cells without de novo infiltration from secondary lymphoid organs.
Cancer Res 72: 3570-3581.
Fan J, Shang D, Han B, Song J, Chen H, & Yang JM (2018). Adoptive Cell
Transfer: Is it a Promising Immunotherapy for Colorectal Cancer?
Theranostics 8: 5784-5800.
Farag SS, Fehniger TA, Ruggeri L, Velardi A, & Caligiuri MA (2002).
Natural killer cell receptors: new biology and insights into the
graft-versus-leukemia effect. Blood 100: 1935-1947.
Fauriat C, Just-Landi S, Mallet F, Arnoulet C, Sainty D, Olive D,
et al. (2007). Deficient expression of NCR in NK cells from acute
myeloid leukemia: Evolution during leukemia treatment and impact of
leukemia cells in NCRdull phenotype induction. Blood 109:323-330.
Fellner C (2012). Ipilimumab (yervoy) prolongs survival in advanced
melanoma: serious side effects and a hefty price tag may limit its use.
P T 37: 503-530.
Fogel LA, Yokoyama WM, & French AR (2013). Natural killer cells in
human autoimmune disorders. Arthritis Res Ther 15: 216.
Foster CE, Colonna M, & Sun PD (2003). Crystal structure of the human
natural killer (NK) cell activating receptor NKp46 reveals structural
relationship to other leukocyte receptor complex immunoreceptors. J Biol
Chem 278: 46081-46086.
Fousek K, & Ahmed N (2015). The Evolution of T-cell Therapies for Solid
Malignancies. Clin Cancer Res 21: 3384-3392.
Francisco LM, Sage PT, & Sharpe AH (2010). The PD-1 pathway in
tolerance and autoimmunity. Immunol Rev 236: 219-242.
Gajewski TF (2015). The Next Hurdle in Cancer Immunotherapy: Overcoming
the Non-T-Cell-Inflamed Tumor Microenvironment. Semin Oncol 42:663-671.
Granger GA, & Weiser RS (1964). Homograft Target Cells: Specific
Destruction in Vitro by Contact Interaction with Immune Macrophages.
Science 145: 1427-1429.
Greenberg AH (1994). The origins of the NK cell, or a Canadian in King
Ivan’s court. Clin Invest Med 17: 626-631.
Groh V, Wu J, Yee C, & Spies T (2002). Tumour-derived soluble MIC
ligands impair expression of NKG2D and T-cell activation. Nature
419: 734-738.
Guilmot A, Bosse J, Carlier Y, & Truyens C (2013). Monocytes play an
IL-12-dependent crucial role in driving cord blood NK cells to produce
IFN-g in response to Trypanosoma cruzi. PLoS Negl Trop Dis 7:e2291.
Gutierrez-Franco J, Hernandez-Gutierrez R, Bueno-Topete MR, Haramati J,
Navarro-Hernandez RE, Escarra-Senmarti M, et al. (2018).
Characterization of B7H6, an endogenous ligand for the NK cell
activating receptor NKp30, reveals the identity of two different soluble
isoforms during normal human pregnancy. Immunobiology 223:57-63.
Gutterman JU (1994). Cytokine therapeutics: lessons from interferon
alpha. Proc Natl Acad Sci U S A 91: 1198-1205.
Gutterman JU, Blumenschein GR, Alexanian R, Yap HY, Buzdar AU,
Cabanillas F, et al. (1980). Leukocyte interferon-induced tumor
regression in human metastatic breast cancer, multiple myeloma, and
malignant lymphoma. Ann Intern Med 93: 399-406.
Halfteck GG, Elboim M, Gur C, Achdout H, Ghadially H, & Mandelboim O
(2009). Enhanced in vivo growth of lymphoma tumors in the absence of the
NK-activating receptor NKp46/NCR1. J Immunol 182: 2221-2230.
Hartmann J, Tran TV, Kaudeer J, Oberle K, Herrmann J, Quagliano I,
et al. (2012). The stalk domain and the glycosylation status of the
activating natural killer cell receptor NKp30 are important for ligand
binding. J Biol Chem 287: 31527-31539.
Hay AE, & Cheung MC (2019). CAR T-cells: costs, comparisons, and
commentary. J Med Econ 22: 613-615.
Hecht ML, Rosental B, Horlacher T, Hershkovitz O, De Paz JL, Noti
C, et al. (2009). Natural cytotoxicity receptors NKp30, NKp44 and
NKp46 bind to different heparan sulfate/heparin sequences. J Proteome
Res 8: 712-720.
Hellstrom IE, Hellstrom KE, Pierce GE, & Bill AH (1968). Demonstration
of cell-bound and humoral immunity against neuroblastoma cells. Proc
Natl Acad Sci U S A 60: 1231-1238.
Hermann E, Alonso-Vega C, Berthe A, Truyens C, Flores A, Cordova
M, et al. (2006). Human congenital infection with Trypanosoma
cruzi induces phenotypic and functional modifications of cord blood NK
cells. Pediatr Res 60: 38-43.
Hermann E, Berthe A, Truyens C, Alonso-Vega C, Parrado R, Torrico
F, et al. (2010). Killer cell immunoglobulin-like receptor
expression induction on neonatal CD8(+) T cells in vitro and following
congenital infection with Trypanosoma cruzi. Immunology 129:418-426.
Herrmann J, Berberich H, Hartmann J, Beyer S, Davies K, & Koch J
(2014). Homo-oligomerization of the activating natural killer cell
receptor NKp30 ectodomain increases its binding affinity for cellular
ligands. J Biol Chem 289: 765-777.
Hershkovitz O, Jarahian M, Zilka A, Bar-Ilan A, Landau G, Jivov S,
et al. (2008). Altered glycosylation of recombinant NKp30 hampers
binding to heparan sulfate: a lesson for the use of recombinant
immunoreceptors as an immunological tool. Glycobiology 18:28-41.
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB,
et al. (2010). Improved survival with ipilimumab in patients with
metastatic melanoma. N Engl J Med 363: 711-723.
Hollyoake M, Campbell RD, & Aguado B (2005). NKp30 (NCR3) is a
pseudogene in 12 inbred and wild mouse strains, but an expressed gene in
Mus caroli. Mol Biol Evol 22: 1661-1672.
Hua CK, Gacerez AT, Sentman CL, & Ackerman ME (2017). Development of
unique cytotoxic chimeric antigen receptors based on human scFv
targeting B7H6. Protein Eng Des Sel 30: 713-721.
Jarahian M, Fiedler M, Cohnen A, Djandji D, Hammerling GJ, Gati C,
et al. (2011). Modulation of NKp30- and NKp46-mediated natural killer
cell responses by poxviral hemagglutinin. PLoS Pathog 7:e1002195.
Jiang T, Zhou C, & Ren S (2016). Role of IL-2 in cancer immunotherapy.
Oncoimmunology 5: e1163462.
Josephs SF, Ichim TE, Prince SM, Kesari S, Marincola FM, Escobedo
AR, et al. (2018). Unleashing endogenous TNF-alpha as a cancer
immunotherapeutic. J Transl Med 16: 242.
Joyce MG, Tran P, Zhuravleva MA, Jaw J, Colonna M, & Sun PD (2011).
Crystal structure of human natural cytotoxicity receptor NKp30 and
identification of its ligand binding site. Proc Natl Acad Sci U S A
108: 6223-6228.
Kaifu T, Escaliere B, Gastinel LN, Vivier E, & Baratin M (2011).
B7-H6/NKp30 interaction: a mechanism of alerting NK cells against
tumors. Cell Mol Life Sci 68: 3531-3539.
Kellner C, Maurer T, Hallack D, Repp R, van de Winkel JG, Parren
PW, et al. (2012). Mimicking an induced self phenotype by coating
lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity. J
Immunol 189: 5037-5046.
Kiessling R, Klein E, & Wigzell H (1975). ”Natural” killer cells in the
mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia
cells. Specificity and distribution according to genotype. Eur J Immunol
5: 112-117.
Koch J, Steinle A, Watzl C, & Mandelboim O (2013). Activating natural
cytotoxicity receptors of natural killer cells in cancer and infection.
Trends Immunol 34: 182-191.
Kohidai L, & Csaba G (1998). Chemotaxis and chemotactic selection
induced with cytokines (IL-8, RANTES and TNF-alpha) in the unicellular
Tetrahymena pyriformis. Cytokine 10: 481-486.
Kruse PH, Matta J, Ugolini S, & Vivier E (2014). Natural cytotoxicity
receptors and their ligands. Immunol Cell Biol 92: 221-229.
Lanier LL (2009). DAP10- and DAP12-associated receptors in innate
immunity. Immunol Rev 227: 150-160.
Leung W (2014). Infusions of allogeneic natural killer cells as cancer
therapy. Clin Cancer Res 20: 3390-3400.
Li Y, Wang Q, & Mariuzza RA (2011). Structure of the human activating
natural cytotoxicity receptor NKp30 bound to its tumor cell ligand
B7-H6. J Exp Med 208: 703-714.
Linnartz-Gerlach B, Kopatz J, & Neumann H (2014). Siglec functions of
microglia. Glycobiology 24: 794-799.
Linnartz B, Wang Y, & Neumann H (2010). Microglial immunoreceptor
tyrosine-based activation and inhibition motif signaling in
neuroinflammation. Int J Alzheimers Dis 2010.
Lorenzo-Herrero S, Lopez-Soto A, Sordo-Bahamonde C, Gonzalez-Rodriguez
AP, Vitale M, & Gonzalez S (2018). NK Cell-Based Immunotherapy in
Cancer Metastasis. Cancers (Basel) 11.
Mantovani S, Mele D, Oliviero B, Barbarini G, Varchetta S, & Mondelli
MU (2015). NKp30 isoforms in patients with chronic hepatitis C virus
infection. Immunology 146: 234-242.
Mantovani S, Oliviero B, Lombardi A, Varchetta S, Mele D, Sangiovanni
A, et al. (2019). Deficient Natural Killer Cell NKp30-Mediated
Function and Altered NCR3 Splice Variants in Hepatocellular Carcinoma.
Hepatology 69: 1165-1179.
Mavoungou E, Held J, Mewono L, & Kremsner PG (2007). A Duffy
binding-like domain is involved in the NKp30-mediated recognition of
Plasmodium falciparum-parasitized erythrocytes by natural killer cells.
J Infect Dis 195: 1521-1531.
McDermott DF, & Atkins MB (2006). Interleukin-2 therapy of metastatic
renal cell carcinoma–predictors of response. Semin Oncol 33:583-587.
Memmer S, Weil S, Beyer S, Zoller T, Peters E, Hartmann J, et al.(2016). The Stalk Domain of NKp30 Contributes to Ligand Binding and
Signaling of a Preassembled NKp30-CD3zeta Complex. J Biol Chem
291: 25427-25438.
Minty A, Chalon P, Derocq JM, Dumont X, Guillemot JC, Kaghad M, et
al. (1993). Interleukin-13 is a new human lymphokine regulating
inflammatory and immune responses. Nature 362: 248-250.
Molina A (2008). A decade of rituximab: improving survival outcomes in
non-Hodgkin’s lymphoma. Annu Rev Med 59: 237-250.
Morandi F, Amoroso L, Dondero A, Castriconi R, Parodi S, Luksch R,
et al. (2018). Updated clinical and biological information from the
two-stage phase II study of imatinib mesylate in subjects with
relapsed/refractory neuroblastoma. Oncoimmunology 7: e1468953.
Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, et
al. (2001). Activating receptors and coreceptors involved in human
natural killer cell-mediated cytolysis. Annu Rev Immunol 19:197-223.
Moretta L, Ciccone E, Mingari MC, Biassoni R, & Moretta A (1994). Human
natural killer cells: origin, clonality, specificity, and receptors. Adv
Immunol 55: 341-380.
Mortara L, Balza E, Bruno A, Poggi A, Orecchia P, & Carnemolla B
(2018). Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting:
Contribution of Innate, Adaptive and Immunosuppressive Cells in the
Anti-tumor Efficacy. Front Immunol 9: 2905.
Nagasawa DT, Fong C, Yew A, Spasic M, Garcia HM, Kruse CA, et al.(2012). Passive immunotherapeutic strategies for the treatment of
malignant gliomas. Neurosurg Clin N Am 23: 481-495.
Nagler A, Lanier LL, & Phillips JH (1990). Constitutive expression of
high affinity interleukin 2 receptors on human CD16-natural killer cells
in vivo. J Exp Med 171: 1527-1533.
Neville MJ, & Campbell RD (1999). A new member of the Ig superfamily
and a V-ATPase G subunit are among the predicted products of novel genes
close to the TNF locus in the human MHC. J Immunol 162:4745-4754.
Ni L, & Lu J (2018). Interferon gamma in cancer immunotherapy. Cancer
Med 7: 4509-4516.
Orange JS (2008). Formation and function of the lytic NK-cell
immunological synapse. Nat Rev Immunol 8: 713-725.
Orange JS (2013). Natural killer cell deficiency. J Allergy Clin Immunol
132: 515-525.
Orange JS, Ramesh N, Remold-O’Donnell E, Sasahara Y, Koopman L, Byrne
M, et al. (2002). Wiskott-Aldrich syndrome protein is required
for NK cell cytotoxicity and colocalizes with actin to NK
cell-activating immunologic synapses. Proc Natl Acad Sci U S A
99: 11351-11356.
Parodi M, Favoreel H, Candiano G, Gaggero S, Sivori S, Mingari MC,
et al. (2019). NKp44-NKp44 Ligand Interactions in the Regulation of
Natural Killer Cells and Other Innate Lymphoid Cells in Humans. Front
Immunol 10: 719.
Paul S, & Lal G (2017). The Molecular Mechanism of Natural Killer Cells
Function and Its Importance in Cancer Immunotherapy. Front Immunol
8: 1124.
Pegram HJ, Andrews DM, Smyth MJ, Darcy PK, & Kershaw MH (2011).
Activating and inhibitory receptors of natural killer cells. Immunol
Cell Biol 89: 216-224.
Pende D, Parolini S, Pessino A, Sivori S, Augugliaro R, Morelli L,
et al. (1999). Identification and molecular characterization of NKp30,
a novel triggering receptor involved in natural cytotoxicity mediated by
human natural killer cells. J Exp Med 190: 1505-1516.
Peng LS, Zhang JY, Teng YS, Zhao YL, Wang TT, Mao FY, et al.(2017). Tumor-Associated Monocytes/Macrophages Impair NK-Cell Function
via TGFbeta1 in Human Gastric Cancer. Cancer Immunol Res 5:248-256.
Perricone C, De Carolis C, Giacomelli R, Zaccari G, Cipriani P, Bizzi
E, et al. (2007). High levels of NK cells in the peripheral blood
of patients affected with anti-phospholipid syndrome and recurrent
spontaneous abortion: a potential new hypothesis. Rheumatology (Oxford)
46: 1574-1578.
Pesce S, Tabellini G, Cantoni C, Patrizi O, Coltrini D, Rampinelli
F, et al. (2015). B7-H6-mediated downregulation of NKp30 in NK
cells contributes to ovarian carcinoma immune escape. Oncoimmunology
4: e1001224.
Phillips M, Romeo F, Bitsaktsis C, & Sabatino D (2016). B7H6-derived
peptides trigger TNF-alpha-dependent immunostimulatory activity of
lymphocytic NK92-MI cells. Biopolymers 106: 658-672.
Pogge von Strandmann E, Simhadri VR, von Tresckow B, Sasse S, Reiners
KS, Hansen HP, et al. (2007). Human leukocyte
antigen-B-associated transcript 3 is released from tumor cells and
engages the NKp30 receptor on natural killer cells. Immunity
27: 965-974.
Poli A, Michel T, Theresine M, Andres E, Hentges F, & Zimmer J (2009).
CD56bright natural killer (NK) cells: an important NK cell subset.
Immunology 126: 458-465.
Prada N, Antoni G, Commo F, Rusakiewicz S, Semeraro M, Boufassa F,
et al. (2013). Analysis of NKp30/NCR3 isoforms in untreated
HIV-1-infected patients from the ANRS SEROCO cohort. Oncoimmunology
2: e23472.
Quattrocchi KB, Miller CH, Cush S, Bernard SA, Dull ST, Smith M,
et al. (1999). Pilot study of local autologous tumor infiltrating
lymphocytes for the treatment of recurrent malignant gliomas. J
Neurooncol 45: 141-157.
Robertson MJ, Caligiuri MA, Manley TJ, Levine H, & Ritz J (1990). Human
natural killer cell adhesion molecules. Differential expression after
activation and participation in cytolysis. J Immunol 145:3194-3201.
Rosenberg SA (2014). IL-2: the first effective immunotherapy for human
cancer. J Immunol 192: 5451-5458.
Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen
SE, et al. (1985). Observations on the systemic administration of
autologous lymphokine-activated killer cells and recombinant
interleukin-2 to patients with metastatic cancer. N Engl J Med
313: 1485-1492.
Rusakiewicz S, Perier A, Semeraro M, Pitt JM, Pogge von Strandmann E,
Reiners KS, et al. (2017). NKp30 isoforms and NKp30 ligands are
predictive biomarkers of response to imatinib mesylate in metastatic
GIST patients. Oncoimmunology 6: e1137418.
Sabry M, & Lowdell MW (2013). Tumor-primed NK cells: waiting for the
green light. Front Immunol 4: 408.
Sathler-Avelar R, Lemos EM, Reis DD, Medrano-Mercado N, Araujo-Jorge TC,
Antas PR, et al. (2003). Phenotypic features of peripheral blood
leucocytes during early stages of human infection with Trypanosoma
cruzi. Scand J Immunol 58: 655-663.
Sato M, Ohashi J, Tsuchiya N, Tadokoro K, Juji T, Hanaoka K, et
al. (2001). Identification of novel single nucleotide substitutions in
the NKp30 gene expressed in human natural killer cells. Tissue Antigens
58: 255-258.
Schrodinger, LLC (2015). The PyMOL Molecular Graphics System, Version
1.8.
Semeraro M, Rusakiewicz S, Minard-Colin V, Delahaye NF, Enot D, Vely
F, et al. (2015). Clinical impact of the NKp30/B7-H6 axis in
high-risk neuroblastoma patients. Sci Transl Med 7: 283ra255.
Semeraro M, Rusakiewicz S, Zitvogel L, & Kroemer G (2015). Natural
killer cell mediated immunosurveillance of pediatric neuroblastoma.
Oncoimmunology 4: e1042202.
Shanafelt TD, Wang XV, Kay NE, Hanson CA, O’Brien S, Barrientos J,
et al. (2019). Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic
Lymphocytic Leukemia. N Engl J Med 381: 432-443.
Sharpe M, & Mount N (2015). Genetically modified T cells in cancer
therapy: opportunities and challenges. Dis Model Mech 8:337-350.
Shemesh A, Brusilovsky M, Kundu K, Ottolenghi A, Campbell KS, &
Porgador A (2018). Splice variants of human natural cytotoxicity
receptors: novel innate immune checkpoints. Cancer Immunol Immunother
67: 1871-1883.
Siegel RL, Miller KD, & Jemal A (2019). Cancer statistics, 2019. CA
Cancer J Clin 69: 7-34.
Siewiera J, Gouilly J, Hocine HR, Cartron G, Levy C, Al-Daccak R,
et al. (2015). Natural cytotoxicity receptor splice variants
orchestrate the distinct functions of human natural killer cell
subtypes. Nat Commun 6: 10183.
Souza-Fonseca-Guimarães F, Cursons J, & Huntington ND (2019). The
Emergence of Natural Killer Cells as a Major Target in Cancer
Immunotherapy. Trends Immunol 40: 142-158.
Stinchcombe JC, & Griffiths GM (2007). Secretory mechanisms in
cell-mediated cytotoxicity. Annu Rev Cell Dev Biol 23: 495-517.
Thiam A, Baaklini S, Mbengue B, Nisar S, Diarra M, Marquet S, et
al. (2018). NCR3 polymorphism, haematological parameters, and severe
malaria in Senegalese patients. PeerJ 6: e6048.
Tompkins WA (1999). Immunomodulation and therapeutic effects of the oral
use of interferon-alpha: mechanism of action. J Interferon Cytokine Res
19: 817-828.
Topham NJ, & Hewitt EW (2009). Natural killer cell cytotoxicity: how do
they pull the trigger? Immunology 128: 7-15.
Trinchieri G (1989). Biology of natural killer cells. Adv Immunol
47: 187-376.
Tsurushima H, Liu SQ, Tuboi K, Matsumura A, Yoshii Y, Nose T, et
al. (1999). Reduction of end-stage malignant glioma by injection with
autologous cytotoxic T lymphocytes. Jpn J Cancer Res 90:536-545.
Vivier E, Ugolini S, Blaise D, Chabannon C, & Brossay L (2012).
Targeting natural killer cells and natural killer T cells in cancer. Nat
Rev Immunol 12: 239-252.
Walk J, & Sauerwein RW (2019). Activatory Receptor NKp30 Predicts NK
Cell Activation During Controlled Human Malaria Infection. Front Immunol
10: 2864.
Watzl C, & Long EO (2010). Signal transduction during activation and
inhibition of natural killer cells. Curr Protoc Immunol 11:Unit 11 19B.
Whiteside TL, & Herberman RB (1994). Role of human natural killer cells
in health and disease. Clin Diagn Lab Immunol 1: 125-133.
Wolpe SD, Davatelis G, Sherry B, Beutler B, Hesse DG, Nguyen HT,
et al. (1988). Macrophages secrete a novel heparin-binding protein with
inflammatory and neutrophil chemokinetic properties. J Exp Med
167: 570-581.
Wu MR, Zhang T, Gacerez AT, Coupet TA, DeMars LR, & Sentman CL (2015).
B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and
Host Antitumor Immunity. J Immunol 194: 5305-5311.
Xu Z, Shen J, Wang MH, Yi T, Yu Y, Zhu Y, et al. (2016).
Comprehensive molecular profiling of the B7 family of immune-regulatory
ligands in breast cancer. Oncoimmunology 5: e1207841.
Yan WL, Shen KY, Tien CY, Chen YA, & Liu SJ (2017). Recent progress in
GM-CSF-based cancer immunotherapy. Immunotherapy 9: 347-360.
Yokoyama WM, & Kim S (2006). Licensing of natural killer cells by
self-major histocompatibility complex class I. Immunol Rev 214:143-154.
Zhang B, Sun J, Yao X, Li J, Tu Y, Yao F, et al. (2018).
Knockdown of B7H6 inhibits tumor progression in triple-negative breast
cancer. Oncol Lett 16: 91-96.
Zhang T, & Sentman CL (2013). NKp30 receptor targeted therapeuticsed.
Organization W.I.P.
Zhang T, Wu MR, & Sentman CL (2012). An NKp30-based chimeric antigen
receptor promotes T cell effector functions and antitumor efficacy in
vivo. J Immunol 189: 2290-2299.
Zhou Y, Xu Y, Chen L, Xu B, Wu C, & Jiang J (2015). B7-H6 expression
correlates with cancer progression and patient’s survival in human
ovarian cancer. Int J Clin Exp Pathol 8: 9428-9433.